Daniel Peckham
Overview
Explore the profile of Daniel Peckham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whitaker P, Gibson A, Farrell J, Gillgrass L, Meng X, Peckham D, et al.
J Allergy Clin Immunol Pract
. 2024 Dec;
13(3):594-609.e8.
PMID: 39674278
Background: Piperacillin-tazobactam is used in patients with cystic fibrosis to treat recurrent respiratory infections. Exposure is associated with a high frequency of nonimmediate hypersensitivity. Objective: To assess the applicability of...
2.
Topping J, Lara-Reyna S, Ibbotson A, Jarosz-Griffiths H, Chang L, Poulter J, et al.
Clin Exp Immunol
. 2024 Dec;
219(1).
PMID: 39657685
Introduction: The apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is crucial for inflammasome assembly and activation of several inflammasomes, including NLRP3. ASC aggregates are detected in human sera...
3.
Spoletini G, Webster C, Burke N, Farrell E, Robson E, Denton M, et al.
ERJ Open Res
. 2024 Dec;
10(6).
PMID: 39655178
https://bit.ly/3xSHCD9.
4.
Prevalence and Distribution of Musculoskeletal Symptoms in Cystic Fibrosis and Impacts on Daily Life
Clarke E, Taylor J, Watson P, Freeston J, Jones A, Peckham D, et al.
Pediatr Pulmonol
. 2024 Dec;
60(1):e27418.
PMID: 39620372
Background: Musculoskeletal problems are reported in the literature as a common problem for people with cystic fibrosis, with a range of aetiologies including an inflammatory arthritis. However, accurate data on...
5.
Jarosz-Griffiths H, Gillgrass L, Caley L, Spoletini G, Clifton I, Etherington C, et al.
PLoS One
. 2024 May;
19(5):e0304555.
PMID: 38820269
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also...
6.
Burgel P, Ballmann M, Drevinek P, Heijerman H, Jung A, Mainz J, et al.
BMJ Open Respir Res
. 2024 May;
11(1).
PMID: 38702073
The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung disease characterised by acute and chronic infections, the accumulation of mucus, airway inflammation, structural damage and...
7.
Edwards A, King M, Noakes C, Peckham D, Lopez-Garcia M
Risk Anal
. 2024 Mar;
44(9):2125-2147.
PMID: 38501447
The Wells-Riley model has been widely used to estimate airborne infection risk, typically from a deterministic point of view (i.e., focusing on the average number of infections) or in terms...
8.
Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M, et al.
Hepatology
. 2023 Nov;
79(5):1220-1238.
PMID: 37934656
Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF...
9.
Calthorpe R, Goodchild N, Gleetus V, Premakumar V, Hayee B, Elliott Z, et al.
NIHR Open Res
. 2023 Oct;
3:18.
PMID: 37881465
Background: Gastrointestinal symptoms in cystic fibrosis (CF) are common and intrusive to daily life. Relieving gastrointestinal symptoms was identified as an important research priority and previously explored in an international...
10.
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, et al.
Front Pharmacol
. 2023 May;
14:1207356.
PMID: 37205908
[This corrects the article DOI: 10.3389/fphar.2022.877118.].